Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells

Targeted protein degradation is a rapidly advancing and expanding therapeutic approach. Drugs that degrade GSPT1 via the CRL4(CRBN) ubiquitin ligase are a new class of cancer therapy in active clinical development with evidence of activity against acute myeloid leukemia in early-phase trials. Howeve...

Descripción completa

Detalles Bibliográficos
Autores principales: Sellar, Rob S., Sperling, Adam S., Słabicki, Mikołaj, Gasser, Jessica A., McConkey, Marie E., Donovan, Katherine A., Mageed, Nada, Adams, Dylan N., Zou, Charles, Miller, Peter G., Dutta, Ravi K., Boettcher, Steffen, Lin, Amy E., Sandoval, Brittany, Quevedo Barrios, Vanessa A., Kovalcik, Veronica, Koeppel, Jonas, Henderson, Elizabeth K., Fink, Emma C., Yang, Lu, Chan, Anthony, Pokharel, Sheela Pangeni, Bergstrom, Erik J., Burt, Rajan, Udeshi, Namrata D., Carr, Steven A., Fischer, Eric S., Chen, Chun-Wei, Ebert, Benjamin L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374383/
https://www.ncbi.nlm.nih.gov/pubmed/35763353
http://dx.doi.org/10.1172/JCI153514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374383/
https://www.ncbi.nlm.nih.gov/pubmed/35763353
http://dx.doi.org/10.1172/JCI153514

Ejemplares similares